pantoprazole has been researched along with Acute Coronary Syndrome in 7 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Co-administration of pantoprazole may enhance the antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome undergoing PCI." | 9.14 | Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. ( Bielis, L; Boinska, J; Budzyński, J; Kasprzak, M; Koziński, M; Kubica, J; Marciniak, A; Plazuk, W; Rość, D; Siller-Matula, J, 2009) |
| "This study sought to compare the effect of 2 proton pump inhibitors (PPIs) on platelet response to clopidogrel after coronary stenting for non-ST-segment elevation acute coronary syndrome (NSTE ACS)." | 5.14 | Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. ( Alessi, MC; Bali, L; Bonnet, JL; Brissy, O; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J, 2009) |
| "Co-administration of pantoprazole may enhance the antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome undergoing PCI." | 5.14 | Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. ( Bielis, L; Boinska, J; Budzyński, J; Kasprzak, M; Koziński, M; Kubica, J; Marciniak, A; Plazuk, W; Rość, D; Siller-Matula, J, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, YJ | 1 |
| Kim, N | 1 |
| Jang, IJ | 1 |
| Cho, JY | 1 |
| Nam, RH | 1 |
| Park, JH | 1 |
| Jo, HJ | 1 |
| Yoon, H | 1 |
| Shin, CM | 1 |
| Park, YS | 1 |
| Lee, DH | 1 |
| Jung, HC | 1 |
| Juurlink, D | 1 |
| Yao, DK | 1 |
| Chen, H | 1 |
| Wang, L | 1 |
| Li, HW | 1 |
| Wang, LX | 1 |
| Cuisset, T | 1 |
| Frere, C | 1 |
| Quilici, J | 1 |
| Poyet, R | 1 |
| Gaborit, B | 1 |
| Bali, L | 1 |
| Brissy, O | 1 |
| Morange, PE | 1 |
| Alessi, MC | 1 |
| Bonnet, JL | 1 |
| Kasprzak, M | 1 |
| Koziński, M | 1 |
| Bielis, L | 1 |
| Boinska, J | 1 |
| Plazuk, W | 1 |
| Marciniak, A | 1 |
| Budzyński, J | 1 |
| Siller-Matula, J | 1 |
| Rość, D | 1 |
| Kubica, J | 1 |
| Wu, H | 1 |
| Jing, Q | 1 |
| Wang, J | 1 |
| Guo, X | 1 |
| Canpolat, U | 1 |
| Şahiner, L | 1 |
| Aytemir, K | 1 |
| Oto, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT02733640] | 42 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention[NCT01812330] | Phase 3 | 180 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| Institute of Emergency and Critical Care Medicine , School of Yang-Ming University[NCT01588886] | 9,000 participants (Actual) | Observational | 2012-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for pantoprazole and Acute Coronary Syndrome
| Article | Year |
|---|---|
Pantoprazole Does Not Reduce the Antiplatelet Effect of Clopidogrel: A Randomized Controlled Trial in Korea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Aged; Clopidogrel; Cytochrome P-45 | 2017 |
Comparison of Intravenous plus Oral Pantoprazole Therapy and Oral Pantoprazole Alone for Preventing Gastrointestinal Bleeding in Acute Coronary Syndrome Patients with High Bleeding Risk.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Administration, Intravenous; Admin | 2015 |
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Corona | 2009 |
Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Corona | 2009 |
Pantoprazole for the prevention of gastrointestinal bleeding in high-risk patients with acute coronary syndromes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Age Factors; Aged; Anticoagulants; | 2011 |
2 other studies available for pantoprazole and Acute Coronary Syndrome
| Article | Year |
|---|---|
Clopidogrel and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Clinical Trials as Topic; Clopidog | 2014 |
Allergic reaction to proton pump ınhibitor: pantoprazole induced Kounis syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Adult; Drug Hypersensitivity; Huma | 2012 |